-
Research frontiers| in the same boat! The MDT model helps the diagnosis and treatment of metastatic prostate cancer
Time of Update: 2022-10-20
Editor: Mumu WangReview: LRExecution: UniIn recent years, the preferred treatment for patients with metastatic prostate cancer (mPC) has shifted from androgen deprivation therapy (ADT) alone to ADT combination.
-
Clinically necessary PD-1/PD-L1 monoclonal antibody consensus for clinical application in urogenital tumors
Time of Update: 2022-10-20
Therefore, the Urology Health Promotion Branch of the China Medical Promotion Association and the Urology Professional Committee of the Chinese Research Hospital Association formulated this consensus on diagnosis and treatment safety, hoping to escort the clinical application of immunotherapy in the population of urogenital tumors 。 The consensus focuses on the guarantee of conditions, patient management, selection of the indicated population, efficacy evaluation, monitoring and management of related adverse reactions, and the treatment of complications/unexpected events.
-
Overview and prospect of application of ctDNA technology in colorectal cancer
Time of Update: 2022-10-20
Ann translational Med 3:235, 2015Editor: YoushiReview: Jiang ZhouTypesetting: YoushiExecution: Small gardenENDAs shown in Figure 1, ctDNA technology can be mainly used in clinical practice in the fields of MRD monitoring, efficacy prediction in metastatic CRC, detection of acquired drug resistance, and guidance on treatment re-challenge.
-
Professor Baili: The FRESCO-2 study shines ESMO, and the status of fruquintinib as the third-line standard treatment for advanced bowel cancer is unshakable
Time of Update: 2022-10-20
Create brilliance again: looking forward to fruquintinib "going abroad and going to the world"From FRESCO research to FRESCO-2 research, fruquintinib, a small molecule anti-angiogenesis-targeted drug independently developed in China, has reached the international top stage, fully verifying the consistent efficacy and safety of fruquintinib in the treatment of advanced bowel cancer patients of different races and regions around the world, indicating that the quality of fruquintinib research data is reliable and the results are reproducible.
-
JCO (IF=51) Wang Jie's team at the Chinese Academy of Medical Sciences has discovered a safe and effective new treatment for non-small cell lung cancer
Time of Update: 2022-10-20
Assessment of PFS curves for two therapies in untreated populations (Figure from Journal of Clinical Oncology) In the final PFS analysis, PFS in the Torpalimab monoclonal antibody group was significantly longer than in the placebo group (median PFS 8.
-
2022 SHS Professor Zhao Weiyi: Everyone gathers firewood and flame high, Ruijin experience in lymphoma diagnosis and treatment
Time of Update: 2022-10-20
Lymphoma is one of the most common malignant tumors in China, due to strong heterogeneity and complex classification, the clinical diagnosis and precision treatment of lymphoma are facing great challe
-
Express The world's first off-the-shelf T-cell therapy is expected to come out! Lymphoma therapy is recommended for marketing in the European Union
Time of Update: 2022-10-20
▲If you have any business needs, please long press to scan the QR code above, or▎WuXi AppTec content team editorAtara Biotherapeutics and Pierre Fabre today announced that their off-the-shelf T-cell immunotherapy Ebvallo (tabelecleucel) has been approved by the European Union Committee for Human Medicines (CHMP) for the treatment of post-transplant lymphoproliferative diseases (EBV+PTLD) associated with Epstein-Barr virus (EBV).
-
Case sharing | exploration of the efficacy and safety of albumin paclitaxel + apatinib in the third-line treatment of SCLC and above
Time of Update: 2022-10-20
6%) 。 A phase II prospective clinical study reported by ASCO in 2022 explored the efficacy and safety of albumin paclitaxel in the first-line treatment of extensive-stage small cell lung cancer, and the results showed that the ORR of carrelizumab combined with albumin-bound paclitaxel and carboplatin as the first-line treatment of ES-SCLC was as high as 81.
-
The IRd regimen helps patients with cytogenetic high-risk MM to achieve lasting remission, with 1q21 amplification case analysis
Time of Update: 2022-10-20
Multiple myeloma (MM) is a malignant disease in which clonal plasma cells proliferate abnormally, often in old age. Patients with MM with 1q21 amplification tend to have a poor prognosis. Ixazomib-bas
-
Express mRNA Cancer Vaccine in combination with Keytruda! Moderna has teamed up with Merck to target melanoma
Time of Update: 2022-10-20
▎WuXi AppTec content team editorMSD and Moderna today jointly announced that Merck has selected to jointly develop and commercialize the individualized cancer vaccine (PCV) mRNA-4157/V940 with Moderna under an existing collaboration and licensing agreement between the two companies.
-
When advanced breast cancer is in remission, which treatment works?
Time of Update: 2022-10-20
Results of PET-CT imaging before the first round of treatmentIn January 2019, after a few months of overall treatment, tests revealed that all of the patient's tumors had disappeared, doctors speculated that chemotherapy and targeted drugs worked, and it was unclear what role the cannabinoids and psilocybin played.
-
JAMA sub-journal: Neoadjuvant intensity-modulated radiotherapy combined with surgery is safe and effective in the treatment of central hepatocellular carcinoma
Time of Update: 2022-10-20
(If you need the original text, you can add Xiaobian WeChat yxj_oncology to obtain) 1JAMA sub-journal: Neoadjuvant intensity-modulated radiotherapy combined with surgery is safe and effective in the treatment of central hepatocellular carcinoma▎Clinical problems:Central hepatocellular carcinoma (HCC) is a specific type of liver cancer that is not well treated with surgery alone, and there is currently no standard adjuvant or neoadjuvant therapy that can improve clinical outcomes.
-
Asia vs West, gastric cancer survival data PK
Time of Update: 2022-10-20
*For medical professionals only, meta-analysis reveals similarities and differences in survival data for gastric cancer patients in Asia and the West. Stomach cancer and gastroesophageal adenocarcinom
-
Tumor-associated neutrophils and neutrophil-targeted cancer therapies
Time of Update: 2022-10-20
Neutrophil-targeted tumor therapy mechanismMechanism (I): Blocks the immune checkpoint of neutrophil (PD1)/PD-L1Targeting PD1/PDL1 is an effective immunotherapy for a variety of cancers, and it can also be used as an effective strategy for targeting TAN.
-
Liu Yong's team at Xiangya Hospital of Central South University and others have discovered a potential mechanism to enhance tumor vaccine response
Time of Update: 2022-10-20
On October 13, 2022, Liu Yong's team at Xiangya Hospital of Central South University and Zhang Nu's team at the University of Texas published a research paper entitled "TGF-β-dependent lymphoid tissue residency of stem-like T cells limits response to tumor vaccine" in Nature Communications。 The study revealed a link between TRM and stem cell-like T cells,which inhibits the migration and effector differentiation of stem cell-like T cells, resulting in weakened anti-tumor immunity.
-
Cohesion, a new chapter of co-spectrum - CSCO Autologous Transplantation Working Group 2022 Tour (Guizhou & Yunnan & Guangxi Station) was a complete success
Time of Update: 2022-10-20
On September 30, 2022, the "CSCO Autologous Transplantation Working Group 2022 Tour - Guizhou & Yunnan & Guangxi Station" hosted by the Chinese Society of Clinical Oncology (CSCO), CSCO Lymphoma Exper
-
【PNAS】The research group of Ma Xianjue/Li Xu of Westlake University revealed a new mechanism of UPR regulation of Hippo signaling pathway mediated tumor progression
Time of Update: 2022-10-20
On October 10, 2022, Ma Xianjue's research group at the School of Life Sciences, Westlake University and Li Xu's research group jointly published a research paper elaborating the molecular mechanism of the Ire1/Xbp1s branch of UPR regulating organ size, intestinal stem cell homeostasis, cell migration and tumorigenesis and development through the Hippo pathway.
-
This article reviews the progress of targeted therapy for breast cancer with low | expression of HER2
Time of Update: 2022-10-20
However, subsequent NSABP B-47 studies (phase III) [6], with the addition of trastuzumab to standard adjuvant therapy, failed to demonstrate a survival benefit for low-HER2-expressing BCs (regardless of IHC 1+/2+) (Table 1).
-
Summary of common anti-tumor drug dosage and adverse reaction treatment!
Time of Update: 2022-10-20
Find "tumor" in the channelAnd pay attentionDownload the Doctor Station App and subscribe anytime, anywhere~*For medical professionals onlyCommon antitumor drug usage and dosage, adverse reactions.
Find "tumor" in the channelAnd pay attentionDownload the Doctor Station App and subscribe anytime, anywhere~*For medical professionals onlyCommon antitumor drug usage and dosage, adverse reactions.
-
Terrible paraneoplastic complications, does targeted therapy work?
Time of Update: 2022-10-20
Malignant tumors such as lung cancer can have some serious paraneoplastic complications, resulting in a very poor prognosis and affecting normal treatment, such as disseminated intravascular coagulation (DIC), which is a complication characterized by thrombosis, bleeding, and thrombocytopenia, and if not treated in time, the patient's life will be in danger.